Back again with another semi-regular column on the Covid-19 pandemic. You can read my first go at this effort here, which was only Tuesday but feels like two weeks ago. I had to double-check the date because days blur together when you work and live in the same place. In this edition: A Bellus Health study is NOT delayed; other studies are; A Pfizer-inspired plea for greater shareholder outreach; and a feel-good story from Agios Pharma.
The coronavirus is seriously disrupting, and in some cases suspending, clinical trials, with significant impacts on drug development. More on this problem for biotech, and what’s being done to fix it, in a moment. First, let’s focus on some good news from one closely followed clinical trial.
About the Author Reprints
